<DOC>
	<DOCNO>NCT02477436</DOCNO>
	<brief_summary>This exploratory clinical study presume optimum usage dosage therapeutic confirmatory study evaluate efficacy safety Avanafil 50mg , 100mg , 200mg placebo administer orally patient erectile dysfunction . In conclusion , Patients erectile dysfunction ( ED ) administer placebo , Avanafil 50mg , 100mg 200mg 30 minute sexual intercourse 8 week .</brief_summary>
	<brief_title>Efficacy Safety Avanafil Patients With Erectile Dysfunction</brief_title>
	<detailed_description>1 . Study design : Prospective , randomize , double blind , placebo-controlled , therapeutic exploratory clinical study Usage &amp; period One capsule administer 30minutes sexual intercourse.It administer day . [ Evaluation endpoint ] 1 . Safety : ① Laboratory test : Hematological Test , Blood chemical Test , Urinalysis Vital sign : blood pressure , pulse rate ③ Adverse event Adverse drug reaction ④12-lead ECG 2 . Efficacy - Primary endpoint ▪ The change erectile function ( EF ) domain score international index erectile function ( IIEF ) - Secondary endpoint ▪ The change success rate sexual encounter profile ( SEP ) questionnaire 2 , questionnaire 3 , questionnaire 4 questionnaire 5 ▪ The change score IIEF questionnaire 3 questionnaire 4 , The change score domain IIEF , GEAQ ( Global efficacy assessment question ) , Normal erectile function ( IIEF EF domain score ≥ 26 ) rate Statistical method 1 . Definition Evaluation population Maximum efficacy evaluation population include subject satisfy inclusion criterion , take investigational product least , visited hospital take investigational product , get result efficacy evaluation . Safety-Evaluation Population consist subject make visit take investigational product get follow-up safety result 2 . Initial Comparability Discrete variables comparatively analyzed χ2-test , Fisher 's exact test , Successive variables comparatively analyzed ANOVA test Kruskal-Wallis test . 3 . Efficacy Evaluation The change EF domain score IIEF : Analysis covariance ( ANCOVA ) , baseline correct , perform check whether difference placebo group Avanafil group change EF domain score . The change score domain IIEF : Analysis covariance ( ANCOVA ) , baseline correct , perform check whether difference placebo group Avanafil group . The change score IIEF questionnaire 3 questionnaire 4 : Analysis covariance ( ANCOVA ) , baseline correct , perform check whether difference placebo group Avanafil group IIEF questionnaire 3 , questionnaire 4 respectively . The change success rate SEP questionnaire 2 , questionnaire 3 , questionnaire 4 questionnaire 5 : Analysis covariance ( ANCOVA ) , baseline correct , perform check whether difference placebo group Avanafil group . GEAQ ( Global Efficacy Assessment Question ) : The difference GEAQ group analyze χ2-test . Normal erectile function ( IIEF EF domain score ≥ 26 ) rate : The difference Normal erectile function rate group analyze χ2-test . The efficacy result analyze Dunnett 's Bonferroni 's multiple comparison test check whether significant difference placebo group Avanafil group . 4 . Safety Evaluation Adverse Events Adverse Drug Reaction : The difference placebo group Avanafil group compare use χ2-test Fisher 's exact test . Adverse event report study subject present WHOART ( World Health Organization Adverse Reaction Terminology ) system organ class . The adverse drug reaction , related investigational product , comparatively verified method . All statistical analysis perform significance level 5 % , test power 80 % two-side test .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>1 . The male subject age 19 ~ 70 history erectile dysfunction least 6 month duration 2 . The subject stable monogamous relationship female partner 3 . Their partner free pregnancy lactation well prevent conception 4 . The subject judge suitable clinical study consequence screen test 5 . The subject consent participate clinical study write 6 . The subject attempt sexual intercourse least 4 time separate day 4 week ' free runin period , whose failure rate 50 % . 7 . The subject whose point 11 25 EF domain IIEF 4 week ' free runin period The following case exclude clinical study . 1 . The subject spinal cord injury underwent radical prostatectomy 2 . The subject whose penis anatomically deform ( Ex : server penile fibrosis , Peyronie 's disease ) 3 . The subject erectile dysfunction due neurogenic endocrine cause ( hyperprolactinemia , low serum testosterone level , etc . ) Hyperprolactinemia : serum prolactin 3 time high upper limit Low Testosterone : serum total testosterone less low limit 4 . The subject uncontrolled major psychiatric disorder accept therapy ( include major depression schizophrenia ) significant neurological abnormality ( neurovascular disorder ) 5 . The subject underwent cancer chemotherapy within 1 year 6 . The subject addict alcohol continuously misuse dependent drug 7 . The subject hepatic dysfunction renal dysfunction follow : Hepatic Dysfunction : GOT GPT ( glutamatepyruvate transaminase ) three time higher upper limit Renal Dysfunction : serum creatinine 2.0mg/dl 8 . The subject uncontrollable diabetes ( FPG &gt; 180mg/dL ) 9 . The subject proliferative diabetic retinopathy 10 . The subject suffer stroke , transient ischemic attack , myocardial infarction , heart failure need medically treat , unstable angina fatal arrhythmia underwent coronary artery bypass graft within 6 month 11 . The subject serious hypotension ( SBP/DBP ( diastolic blood pressure ) less 90/50mmHg sit posture ) uncontrollable severe hypertension ( SBP/DBP 170/100mmHg sit posture ) 12 . The subject hematological disorder likely develop priapism sickle cell disease , multiple myeloma , leukemia 13 . The subject retinitis pigmentosa 14 . The subject suffer serious GI bleeding disorder within 1 year 15 . The subject take Viagra® , Cialis® , Levitra® , Mvix® others within 2 week clinical study 16 . The subject take follow drug ① Nitrate/Nitric oxide ( NO ) donor ( ex . Nitroglycerin , isosorbide mononitrate , amyl nitrate/nitrite , sodium nitroprusside ) ② Androgens ( ex testosterone ) , antiandrogen , trazodone ③ Anticoagulant ( excludes antiplatelet drug ) ④ Erythromycin , itraconazole , ketoconazole , cimetidine , ritonavir , saquinavir , amprenavir , indinavir nelfinavir greatly affect CYP3A4 ( cytochrome P450 isoenzyme 3A4 ) 17 . The subject history hypersensitivity PDE ( phosphodiesterase ) 5 inhibitor whose erectile dysfunction improve 18 . The subject hypoactive sexual desire 19 . The subject intention sexual intercourse 4 time separate day 4 week ' free runin period 20 . The subject take study drug within 30 day clinical study 21 . The subject judge unsuitable clinical study reason</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>